ORG
BenevolentAI Downsizes Operations, Cuts 30% of Workforce Amidst Funding Challenges
BenevolentAI, layoffs, workforce reduction, funding gap, US site closure, AI research, drug discovery
Incyte Invests in Mast Cell Inhibitors with $750M Escient Acquisition
Incyte, Escient, mast cell inhibitors, acquisition, pharmaceutical, drug development, inflammatory diseases, cancer, fibrosis, $750 million
Neurocrine Biosciences and Takeda’s Collaborative Depression Program Achieves Mid-Stage Success
Neurocrine Biosciences, Takeda, depression program, mid-stage success, clinical trials, mental health, pharmaceutical collaboration.
Shimadzu Corporation Expands US Presence with Three New R&D Centers for Pharmaceutical Growth
Shimadzu Corporation, R&D centers, US expansion, pharmaceutical industry, business growth, innovation, technology.
Novartis Appoints Ex-Bristol Myers CEO Giovanni Caforio as Chair: Potential for Future M&A Deals?
Novartis, Bristol Myers, Giovanni Caforio, Chair, Mergers and Acquisitions (M&A), Pharmaceutical Industry, Corporate Strategy, Leadership Change.
Neurocrine-Takeda Collaboration Shows Promise in Alleviating Depression Symptoms in Phase 2 Trials
Neurocrine, Takeda, Phase 2 trials, depression, depression severity, medication, analysts, data detail.
Sanofi’s BTK Inhibitor Succeeds in Phase 3 LUNA Trial, Accelerating Regulatory Approval Race
Sanofi, BTK inhibitor, LUNA trial, phase 3, regulatory approval, clinical development, blood cancer, competition
FDA Rejects Abeona’s PZ-CEL Topical Gene Therapy, Delaying Further Progress
Abeona, PZ-CEL, topical gene therapy, FDA, rejection, delay, clinical trials, EB-101, Epidermolysis Bullosa
ImmunityBio’s Anktiva Receives FDA Approval, Set to Rival Merck in Bladder Cancer Treatment
ImmunityBio, Anktiva, FDA approval, bladder cancer, Merck, cancer treatment, Patrick Soon-Shiong.
FDA Grants Approval to ImmunityBio’s Innovative Combination Therapy for Bladder Cancer
FDA, ImmunityBio, bladder cancer, combination therapy, approval, innovative treatment, immunotherapy, clinical trials